Mark Israel named executive director of Israel Cancer Research Fund

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mark Israel, a pediatric oncologist and translational scientist, was appointed national executive director of the Israel Cancer Research Fund, a nonprofit organization dedicated solely to funding cancer research in Israel.

Israel joins ICRF from the Geisel School of Medicine at Dartmouth College, where he is a professor in the Department of Pediatrics, Medicine, and Molecular and Systems Biology. From 2001 to 2016, Israel served as the director of Dartmouth’s Norris Cotton Cancer Center.

For the last 12 years, Israel has been a volunteer member of the ICRF’s scientific review panel and the chair of the panel that evaluates translational cancer research proposals.

“Cancer research has never been more exciting or promising—and that is particularly true in Israel,” Israel said in a statement. “Israeli science knows no bounds. ICRF provides a singular opportunity to help build more recognition and support for the world-class cancer research of Israeli scientists, and to arm and empower its finest practitioners with the resources necessary to change the world.”

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login